Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Fan W, Philip S, Toth PP, et al. Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300878

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

https://www.ajconline.org/article/S0002-9149(20)30861-4/fulltext

Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results [published online ahead of print, 2020 Jul 1]. Cardiovasc Res. 2020;cvaa184. doi:10.1093/cvr/cvaa184

https://academic.oup.com/cardiovascres/article-abstract/doi/10.1093/cvr/cvaa184/5865857

American College of Cardiology
DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the American College of Cardiology 2020 annual meeting (virtual).

https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=062fc9e4b3a74a9fb1c196a35dad8f3b

Pisaniello AD, Nicholls SJ, Ballantyne CM, Bhatt DL, Wong ND. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. EMJ. 2020;5:29-36.

https://www.emjreviews.com/cardiology/symposium/eicosapentaenoic-acid-atheroprotective-properties-and-the-reduction-of-atherosclerotic-cardiovascular-disease-events/

Wong ND, Fan W, Toth P, Granowitz C, Philip S. REDUCE-IT eligibility and preventable first and total cardiovascular events in the US population: an analysis of the National Health and Nutrition Examination Survey (NHANES) [abstract]. J Am Coll Cardiol 2020;75(11 suppl 1):1954.

http://www.onlinejacc.org/content/75/11_Supplement_1/1954

Lakshmanan S, Shekar C, Dahal S, Onuegbu A, Kinninger A, Cai A, Rezvanizadeh V, Golub I, Birudaraju D, Cherukuri L, Hamal S, Dailing C, Flores F, Roy SK, Nelson J, Budoff MJ. Association of inflammatory markers with baseline coronary plaque volumes by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract]. J Am Coll Cardiol 2020;75(11 suppl 10:1720. 

http://www.onlinejacc.org/content/75/11_Supplement_1/1720

Weintraub WS, Bhatt D, Zhang Z, Zhang C, Sarahfaye D, Boden WE, Steg PG, Miller M, Brinton E, King J, Bress A, Jacobson T, Tardiff JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl in US REDUCE-IT patients [abstract]. J Am Coll Cardiol. 2020;75(11 suppl 1):1914.

http://www.onlinejacc.org/content/75/11_Supplement_1/1914
Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Gregson J, Pocock SJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the annual meeting of the American College of Cardiology, March 16-18, 2019, New Orleans, Louisiana.

Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S, Granowitz C, Navar AM. The Association between Triglycerides and Incident Cardiovascular Disease: What Is “Optimal”? Journal of Clinical Lipidology 2020;14:438-447.

https://www.lipidjournal.com/article/S1933-2874(20)30079-9/fulltext?dgcid=raven_jbs_etoc_email
copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation